The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases

Plantier-Colcher, I.; Dupriez, Brigitte; Simon, Marc A.; Detourmignies, Laurence; Jouet, Jean‐Pierre; Fenaux, Pierre; Bauters, F; Morel, Pierre

doi:10.1038/sj.leu.2401328

Cited by 8 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a separate study, the combination of ifosfamide, epirubicin and etoposide was explored as salvage therapy for 51 patients with relapsed or refractory aggressive NHL, resulting in an objective response rate of 77% with a CR rate of 32% (Zinzani et al , 2002). In another study, a regimen consisting of teniposide, ifosfamide, mitoxantrone, mitoguazone, high‐dose methotrexate, high‐dose cytarabine and prednisolone followed by ASCT for patients with residual disease after induction produced overall response (OR) and CR rates of 72% and 45%, respectively, in 71 patients with relapsed/refractory aggressive NHL (Plantier‐Colcher et al , 1999).…”

Section: Second‐line Treatment Before the Rituximab Eramentioning

confidence: 99%

Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting

Gisselbrecht

2008

Br J Haematol

View full text Add to dashboard Cite

SummaryThe addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy was a milestone in the development of front-line therapy for diffuse large B-cell lymphoma (DLBCL). R-CHOP and equivalent rituximab-containing anthracycline-based regimens are now widely accepted as the standard of care in this setting. However, the optimal treatment for patients with DLBCL relapsing or progressing after front-line therapy is not yet established. This review explores the role of rituximab in the treatment of DLBCL in the salvage setting, as monotherapy, in combination with chemotherapy or novel agents, and in the context of autologous stem cell transplantation (ASCT). Current evidence suggests that rituximab may improve outcomes in several ways: the higher response rates achieved with rituximab-based induction in the salvage setting optimize the number of patients who are able to proceed to high-dose therapy -ASCT; rituximab may improve outcomes following ASCT when used as post-transplantation consolidation/maintenance therapy; and addition of rituximab to salvage regimens may improve outcomes for patients ineligible for transplantation. However, patients refractory to or relapsing after firstline therapy (including rituximab-based regimens) still have a poor prognosis. In conclusion, rituximab in salvage therapy for DLBCL is effective and well tolerated. Ongoing studies will further clarify the optimal use of rituximab in the salvage setting.

show abstract

Section: Second‐line Treatment Before the Rituximab Eramentioning

confidence: 99%

Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting

Gisselbrecht

2008

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…MTX and Ara-C have been widely used in combination for treatment of patients with NHL. [170][171][172][173][174] After tumor regression following conditioning regimens, some tumor cells may recover and enter log phase growth. This stage of cell growth could make lymphoma cells more vulnerable to a combination of antimetabolite treatment.…”

Section: -131mentioning

confidence: 99%

Hematopoietic stem cell gene therapy with drug resistance genes: an update

2005

View full text Add to dashboard Cite

Transfer of drug resistance genes into hematopoietic stem cells (HSCs) has promise for the treatment of a variety of inherited, that is, X-linked severe combined immune deficiency, adenosine deaminase deficiency, thalassemia, and acquired disorders, that is, breast cancer, lymphomas, brain tumors, and testicular cancer. Drug resistance genes are transferred into HSCs either for providing myeloprotection against chemotherapy-induced myelosuppression or for selecting HSCs that are concomitantly transduced with another gene for correction of an inherited disorder. In this review, we describe ongoing experimental approaches, observations from clinical trials, and safety concerns related to the drug resistance gene transfer.

show abstract

“…Today, methotrexate is still commonly used in the treatment of lymphoma, sometimes in combination with cytidine analogs, with which they are known to be particularly synergistic. For example, the integration of methotrexate with or without cytarabine are still used in select combination chemotherapy regimens, most notably in HyperCVAD/MA, which has been used in the treatment of acute lymphoblastic leukemia (ALL) and MCL (33–35), PROMACE‐cytaBOM for large cell lymphoma (36, 37), and the CODOX‐M/IVAC regimen for Burkitt's lymphoma.…”

Section: New Derivatives Of ‘Old’ Favorites – Revisiting the Anti‐folatementioning

confidence: 99%

Developing new drugs for the treatment of lymphoma

O’Connor

2005

European J of Haematology

View full text Add to dashboard Cite

Despite the great progress that has been made over the last several decades in the treatment of lymphoma, the prognosis for patients with relapsed disease, and particular sub‐types of lymphoma like mantle cell and T cell lymphoma, remains quite poor. While major advances in the use of combination chemotherapy, monoclonal antibodies, peripheral blood stem cell transplants, and radioimmunotherapy, have provided new opportunities to alter the natural history of these diseases, and even improve cure rates among elected sub‐populations of patients, these ‘traditional‘ approaches have not benefited all patients, or sub‐types of lymphoma. The incredibly rapid pace of understanding the molecular basis for the discrete sub‐types of both non‐Hodgkin's lymphoma and Hodgkin's Disease is beginning to afford exciting new opportunities to both risk stratify patients, and to identify potentially novel ‘drugable’ targets. These advancements in understanding the major molecular defects in lymphoma, have provided a new context in which we can rethink the use of new and old drugs, and design new ones with unique mechanisms of action. The panoply of new targets and drugs now becoming available for the treatment of lymphoma is truly daunting. A plethora of new small molecules that target bcl‐2, mTOR, histone deactylases, and NF‐kB have shown promising preclinical activity, and are now promising early phase activity. In many cases, the empirical observations from early clinical trials have provided invaluable clues to potentially valuable drugs like bortezomib, depsipeptide, and SAHA, These empirical observations, based on the inclusion of patients with lymphoma on these studies, have thus far proven to be as or more valuable than any other ‘rational’ target based approach. In addition, beyond the novel small molecules affecting unique and heretofore unrecognized biological pathways, there continues to be a robust and important effort to identify new derivatives of older generation drugs with hopefully better activity, and less toxicity. For example, new generation anthracenediones and anti‐folates, and new formations of older drugs like doxorubicin, irinotecan, and vincristine afford new opportunities to favourably change the pharmacokinetic profile of these agents, and improve their overall safety profile. While it would not be possible to address each and every new such drug, we hope to touch on some of the major new themes and agents emerging for the treatment of Hodgkin's Disease and non‐Hodgkin's lymphoma.

show abstract

The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases

Cited by 8 publications

References 12 publications

Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting

Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting

Hematopoietic stem cell gene therapy with drug resistance genes: an update

Developing new drugs for the treatment of lymphoma

Contact Info

Product

Resources

About